Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 63

1.

Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206.

Blum KA, Johnson JL, Niedzwiecki D, Canellos GP, Cheson BD, Bartlett NL.

Leuk Lymphoma. 2007 Jul;48(7):1313-9.

PMID:
17613759
2.

Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma.

Di Bella N, Taetle R, Kolibaba K, Boyd T, Raju R, Barrera D, Cochran EW Jr, Dien PY, Lyons R, Schlegel PJ, Vukelja SJ, Boston J, Boehm KA, Wang Y, Asmar L.

Blood. 2010 Jan 21;115(3):475-80. doi: 10.1182/blood-2009-08-233155. Epub 2009 Nov 19.

3.

A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma - long-term results of a multicenter observation study.

Weigert O, Weidmann E, Mueck R, Bentz M, von Schilling C, Rohrberg R, Jentsch-Ullrich K, Hiddemann W, Dreyling M.

Leuk Lymphoma. 2009 May;50(5):716-22. doi: 10.1080/10428190902856790.

PMID:
19347767
4.

A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma.

Berenson JR, Matous J, Swift RA, Mapes R, Morrison B, Yeh HS.

Clin Cancer Res. 2007 Mar 15;13(6):1762-8.

5.

Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma.

de Vos S, Goy A, Dakhil SR, Saleh MN, McLaughlin P, Belt R, Flowers CR, Knapp M, Hart L, Patel-Donnelly D, Glenn M, Gregory SA, Holladay C, Zhang T, Boral AL.

J Clin Oncol. 2009 Oct 20;27(30):5023-30. doi: 10.1200/JCO.2008.17.7980. Epub 2009 Sep 21.

PMID:
19770386
6.

Treatment of relapsed or refractory Waldenström's macroglobulinemia with bortezomib.

Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, Castritis E, Bitsaktsis A, Pangalis GA.

Haematologica. 2005 Dec;90(12):1655-8.

7.

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.

Orlowski RZ, Nagler A, Sonneveld P, Bladé J, Hajek R, Spencer A, San Miguel J, Robak T, Dmoszynska A, Horvath N, Spicka I, Sutherland HJ, Suvorov AN, Zhuang SH, Parekh T, Xiu L, Yuan Z, Rackoff W, Harousseau JL.

J Clin Oncol. 2007 Sep 1;25(25):3892-901. Epub 2007 Aug 6.

PMID:
17679727
8.

Bortezomib in combination with dexamethasone for patients with relapsed Hodgkin's lymphoma: results of a prematurely closed phase II study (NCT00148018).

Trelle S, Sezer O, Naumann R, Rummel M, Keller U, Engert A, Borchmann P.

Haematologica. 2007 Apr;92(4):568-9.

9.

High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program.

Mikhael JR, Belch AR, Prince HM, Lucio MN, Maiolino A, Corso A, Petrucci MT, Musto P, Komarnicki M, Stewart AK.

Br J Haematol. 2009 Jan;144(2):169-75. doi: 10.1111/j.1365-2141.2008.07409.x. Epub 2008 Nov 19.

PMID:
19036114
10.

Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma.

Zinzani PL, Musuraca G, Tani M, Stefoni V, Marchi E, Fina M, Pellegrini C, Alinari L, Derenzini E, de Vivo A, Sabattini E, Pileri S, Baccarani M.

J Clin Oncol. 2007 Sep 20;25(27):4293-7. Epub 2007 Aug 20.

PMID:
17709797
11.

NF-kappaB-independent down-regulation of XIAP by bortezomib sensitizes HL B cells against cytotoxic drugs.

Kashkar H, Deggerich A, Seeger JM, Yazdanpanah B, Wiegmann K, Haubert D, Pongratz C, Krönke M.

Blood. 2007 May 1;109(9):3982-8. Epub 2006 Dec 21.

12.

Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia.

Faderl S, Rai K, Gribben J, Byrd JC, Flinn IW, O'Brien S, Sheng S, Esseltine DL, Keating MJ.

Cancer. 2006 Sep 1;107(5):916-24.

13.

Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up.

Berenson JR, Yang HH, Vescio RA, Nassir Y, Mapes R, Lee SP, Wilson J, Yellin O, Morrison B, Hilger J, Swift R.

Ann Hematol. 2008 Aug;87(8):623-31. doi: 10.1007/s00277-008-0501-0. Epub 2008 May 8.

PMID:
18463870
14.

Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma: a phase 2 trial of the Minnie Pearl Cancer Research Network.

Hainsworth JD, Spigel DR, Barton J, Farley C, Schreeder M, Hon J, Greco FA.

Cancer. 2008 Aug 15;113(4):765-71. doi: 10.1002/cncr.23606.

15.

Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial.

Chanan-Khan A, Miller KC, Musial L, Padmanabhan S, Yu J, Ailawadhi S, Sher T, Mohr A, Bernstein ZP, Barcos M, Patel M, Iancu D, Lee K, Czuczman MS.

Leuk Lymphoma. 2009 Jul;50(7):1096-101. doi: 10.1080/10428190902912460.

PMID:
19479618
16.

A retrospective analysis of bortezomib therapy for Japanese patients with relapsed or refractory multiple myeloma: beta2-microglobulin associated with time to progression.

Ohguchi H, Sugawara T, Ishikawa I, Okuda M, Tomiya Y, Yamamoto J, Onishi Y, Fujiwara Yamada M, Ishizawa K, Kameoka J, Harigae H.

Int J Hematol. 2009 Apr;89(3):342-7. doi: 10.1007/s12185-009-0279-4. Epub 2009 Mar 19.

PMID:
19296199
17.

Bortezomib in combination with conventional chemotherapeutic agents for multiple myeloma compared with bortezomib alone.

Min CK, Lee MJ, Eom KS, Lee S, Lee JW, Min WS, Kim CC, Kim M, Lim J, Kim Y, Han K.

Jpn J Clin Oncol. 2007 Dec;37(12):961-8. Epub 2007 Dec 21.

PMID:
18156171
18.

Escalation therapy with bortezomib, dexamethasone and bendamustine for patients with relapsed or refractory multiple myeloma.

Fenk R, Michael M, Zohren F, Graef T, Czibere A, Bruns I, Neumann F, Fenk B, Haas R, Kobbe G.

Leuk Lymphoma. 2007 Dec;48(12):2345-51.

PMID:
18067009
19.

Bortezomib, ascorbic acid and melphalan (BAM) therapy for patients with newly diagnosed multiple myeloma: an effective and well-tolerated frontline regimen.

Berenson JR, Yellin O, Woytowitz D, Flam MS, Cartmell A, Patel R, Duvivier H, Nassir Y, Eades B, Abaya CD, Hilger J, Swift RA.

Eur J Haematol. 2009 Jun;82(6):433-9. doi: 10.1111/j.1600-0609.2009.01244.x. Epub 2009 Feb 17.

PMID:
19226361
20.

Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib.

Sood R, Carloss H, Kerr R, Lopez J, Lee M, Druck M, Walters IB, Noga SJ.

Am J Hematol. 2009 Oct;84(10):657-60. doi: 10.1002/ajh.21517.

Supplemental Content

Support Center